These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27216075)

  • 1. Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates.
    Castanheira M; Mendes RE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4770-7. PubMed ID: 27216075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying
    Castanheira M; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031200
    [No Abstract]   [Full Text] [Related]  

  • 3. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
    Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.
    Castanheira M; Farrell SE; Krause KM; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2014; 58(2):833-8. PubMed ID: 24247134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
    Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
    Sader HS; Huband MD; Duncan LR; Flamm RK
    Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
    Castanheira M; Doyle TB; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
    Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
    King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
    Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
    Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
    Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.